Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

usiness Officer.  Mr. Nolan will lead the creation and establishment of InterMune's U.S. Commercial, Business Development and Global Marketing groups.  He will also oversee InterMune's Canadian business and the company's manufacturing and supply chain operations. 
  • On February 19, InterMune reported that the company and Shionogi & Co., Ltd had reached an agreement regarding the material terms of a settlement of the complaint filed by Shionogi against InterMune.  Effective January 1, 2013, InterMune agrees to pay Shionogi a royalty of 4.25% on net sales of Esbriet in the European Union through the remaining period of Orphan Drug exclusivity ending in February 2021.  Shionogi waives any claim against InterMune to royalties on European sales of Esbriet prior to January 1, 2013 and any claim to royalties on Esbriet sales in Canada or in the United States.  The previous agreement provided for a royalty structure on net sales of pirfenidone equal to 6% of net sales for the first and second calendar year following commercialization, 8% of net sales for the third and fourth calendar year following commercialization and 10% of net sales for each subsequent calendar year thereafter.

    • Fourth Quarter and Full Year 2012 Financial Results (Unaudited)
    InterMune reported total revenue in the fourth quarter of 2012 of $8.2 million, compared with $2.7 million in the fourth quarter of 2011, an increase of 204 percent.  Fourth quarter 2012 results included the effect of the approximate 11 percent German price decrease of Esbriet, which became effective on September 15, 2012.  InterMune reported total revenue for the full year 2012 of $26.2 million, compared with $5.4 million in 2011, an increase of 385 percent.  Total revenue in 2011 consisted of $2.8 million of Esbriet revenue and $2.6 million of revenue from the company's research collaboration with Roche, which was completed in June 2011.Research and development (R
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/17/2013)... (PRWEB) May 17, 2013 The paradigm ... complex biological systems that can help predict the adverse ... Dr. Sergey Stepaniants, Head of Computational Biology at the ... biology tools to ensure high-quality genomics when used as ... be applied to complex data sets to identify key ...
    (Date:5/17/2013)... May 17, 2013 Rust removal is one ... non-metal home items could be damaged. To help rust contractors ... of its no-scrubbing rust remover it called Rusterizer. ... available with 10% discount. , My Cleaning Products explained that ... them or by staining them. The first one, it ...
    (Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
    (Date:5/16/2013)... (PRWEB) May 16, 2013 ... Barbara A. Myers, CAE, to the newly created ... her new role, Myers will be responsible for ... and production strategies, advancing the Society’s Member-led and ... and continuing to refine organizational, membership and product ...
    Breaking Biology Technology:Organic-Based Rust Remover Cuts Down Price by 10%, My Cleaning Products Details Mechanics How to Get the Discount 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3ISPE Names Barbara A. Myers, CAE, as Vice President of Professional Development 2
    ... ... That Scientists Can Focus on Novel Research , ... (PRWEB) May 20, 2010 -- DNA2.0 , the leading gene synthesis ... in order to provide customers with a seamless experience from gene synthesis to protein expression ...
    ... surf in colder waters and keep warm for longer, ... wetsuit manufacturer, Spartan. Spartan specialise in wetsuits for ... measurement institute, to understand the science behind how wetsuits ... particular it wanted to improve its windsurfing wetsuits, which ...
    ... CAMBRIDGE, Massachusetts , May ... SHPGY ), the global specialty biopharmaceutical,company, today announced that ... from NORD. Shire was recognized for its efforts to ... enzyme replacement,therapy (ERT) for the treatment of Type 1 ...
    Cached Biology Technology:DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 2DNA2.0 and Blue Sky Biotech Announce Strategic Alliance for Bundled Customer Experience From Gene Synthesis to Purified Protein 3A warmer future for watersports 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 2Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 3Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 4Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection) 5
    (Date:5/16/2013)... Northwestern University scientists have shown a gene involved in ... proper function of the circadian clock. , In ... found the gene, called Ataxin-2, keeps the clock responsible ... the gene, the rhythm of the fruit fly,s sleep-wake ... schedule difficult for the fly. , The discovery ...
    (Date:5/16/2013)... SPARTANBURG, S.C. , May 16, 2013 /PRNewswire/ ... film in combination with a custom thin film ...  the highest forensic quality roll image in the ... market today. Sherlock, an Appendix F Mobile ID ... provides a 95% reduction in size and weight ...
    (Date:5/16/2013)... world are meeting next week in Toronto. The ... latest in research findings about the brain, the ... disorders that affect them., "Canada is a leader ... the best of neuroscience research done here and ... the Canadian Association for Neuroscience. He also reminds ...
    Breaking Biology News(10 mins):Gene involved in neurodegeneration keeps clock running 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2
    ... 26, 2012  Medbox, Inc. (Pinksheets: MDBX) ( www.medboxinc.com ... for 2012. Through their subsidiary, ... dispensing and storage systems, which are designed to ... alternative medicine clinics and doctor,s offices. The systems ...
    ... , RICHLAND, Wash. The Department of Energy,s ... bringing a lab-developed technology that improves research sample ... Consortium announced today that PNNL is receiving a ... consortium is a nationwide network that encourages federal ...
    ... by the College of Agricultural Sciences, The Pennsylvania State University, ... for Abstract Submissions: 1 March 2012 -- The Society ... an abstract for presentation at the 45th SSR Annual Meeting ... Links to the following are to be found on ...
    Cached Biology News:Medbox, Inc. Announces New Product Line for 2012 2PNNL recognized for technology transfer 2
    ...
    Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
    Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
    ... and high speed homogeneous assay for the ... for screening of inhibitors in a high-throughput ... on a fluorescence superquenching technology that does ... universal platform provides flexibility for assaying any ...
    Biology Products: